| European Case Law Identifier: | ECLI:EP:BA:2014:T231713.20140414 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 14 April 2014 | ||||||||
| Case number: | T 2317/13 | ||||||||
| Application number: | 07867601.2 | ||||||||
| IPC class: | A61K 39/395 C07K 16/28 |
||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | C | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Anti-p-selectin antibodies and methods of using the same to treat inflammatory diseases | ||||||||
| Applicant name: | Selexys Pharmaceuticals Corporation | ||||||||
| Opponent name: | - | ||||||||
| Board: | 3.3.04 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Re-establishment of rights (no) Minimally late filed statement of grounds of appeal - admissible Reimbursement of fee for re-establishment of rights (yes) |
||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t132317eu1.html
Date retrieved: 17 May 2021